Corrigendum to "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes".
5924671 - ?
Int J Endocrinol
MetadataShow full item record
[This corrects the article DOI: 10.1155/2014/690783.]. In the article titled “The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes” , there was an error regarding the FRAX® tool, which should be clarified as follows: The article notes: “Even the FRAX (fractures risk assessment tool), an algorithm adopted by the WHO to assess the risk of fractures, does not seem useful in T2D patients .” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations . The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.
AuthorsNapoli, N; Strollo, R; Paladini, A; Briganti, SI; Pozzilli, P; Epstein, S
- Immune Systems